Patient Adherence Experts, Including CMT’s Moses Zonana, Featured On Latest PM360 Issue To Address Key Industry Issues
Source: PM360 • Date August 02, 2018
PM360 asked experts in improving patient adherence to address key issues the industry should know about in 2018, including:
- What barriers are the most prevalent to preventing medication adherence/compliance that pharma should be focused on? What are some lesser-known barriers that deserve more attention?
- What are the keys to creating a successful adherence program? What types of programs or techniques are the most effective in improving adherence? What techniques have been the least effective?
- How can pharma better leverage data and insights to tailor adherence programs to specific patients or general patient populations to ensure they are offering support that patients will use?
- How can pharma better partner with payers, physicians, pharmacists, PBMs, and/or third-party service providers to help improve adherence?
Moses Zonana, CEO of Compliance Meds Technologies, responded to:
How can pharma better partner with payers, physicians, pharmacists, PBMs, and/or third-party service providers to help improve adherence?
“Pharma seems to be in an analysis paralysis stage as it relates to implementation of new practices to improve adherence. They seem inundated by the buzzword of the season, IoT, AR, AI, Alexa, etc. All of those approaches are better than the archaic strategies used in the past, including reminder post-cards and blanket messages.
However, generic pharma doesn’t really have the margins to implement many of the novel approaches—and pharmacies have even narrower margins. In many cases—given price points—those in generic pharma have no choice but to continue with primitive low-cost approaches. But as a solution, especially for single-sourced generics or higher-priced generics, they could entertain funding programs via rebates to payers, third-party service providers, PBMs, and/or pharmacists.
Meanwhile, for branded pharma, value-based contracts will place pharma at risk if they can’t show that the medicine is being taken adequately to achieve targeted outcomes. It is imperative for such brands to take a proactive approach by funding novel ways to improve habits. As an example, pharma can fund a real-time visibility tool that sheds light into daily patient dosing habits and includes interventions and coaching via a third-party focused patient support group.”
Read Full Article Here: https://www.pm360online.com/four-key-questions-about-adherence-compliance/?GTTabs=9